Lipocine Inc. (LPCN) is a Biotechnology company in the Healthcare sector, currently trading at $2.56. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is LPCN = $15 (+485.9% upside).
Valuation: LPCN trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Financials: revenue is $2M, -376.3%/yr average growth. Net income is $10M (loss), growing at -38441.3%/yr. Net profit margin is -487.1% (negative). Gross margin is -334.3% (-434.3 pp trend).
Balance sheet: total debt is $0 against $14M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.68 (strong liquidity). Debt-to-assets is 0%. Total assets: $17M.
Analyst outlook: 7 / 9 analysts rate LPCN as buy (78%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
